Prevalence and risk factors of muscle complications secondary to statins

El‐Salem, Khalid; Ababneh, Bashar; Rudnicki, Stacy A.; Malkawi, Ahmad B.; Alrefai, Ali; Khader, Yousef; Saadeh, Ruba; Saydam, Mohammad

doi:10.1002/mus.22205

Cited by 74 publications

(52 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This estimation can be refuted and supported by existing literature. Clinical trials, which report the occurrence of SAME between 1 and 5 %, often exclude patients with a previous history of statin-related myalgia and lack formal assessments or questionnaires targeting muscle-related symptoms [41][42][43][44][45][46][47][48]. In contrast, observational studies may overestimate the rate of SAME, attributing symptoms with another etiology to statin therapy [48].…”

Section: Statin-associated Muscle Effectsmentioning

confidence: 95%

Current Drug Treatment of Hyperlipidemia in Older Adults

2015

View full text Add to dashboard Cite

Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death, especially in older adults. Managing modifiable risk factors (e.g., hyperlipidemia, hypertension) remains the primary approach to prevent ASCVD events and ASCVD-related mortality. Statins are generally considered one of the most effective approaches to reduce ASCVD risk, especially for secondary prevention, yet remain underutilized in older adults. The evidence to support statin therapy in older adults is less robust than in their younger counterparts, especially in individuals aged 75 years and older. Recent lipid guidelines have raised this concern, yet statin therapy is recommended in 'at risk' older adults. Determining which older adults should receive statin therapy for primary prevention of ASCVD is challenging, as the currently available risk estimation tools are of limited use in those aged over 75 years. Furthermore, non-statin therapies have been de-emphasized in recent clinical practice guidelines and remain understudied in the older adult population. This is unfortunate given that older adults are less likely to tolerate moderate- to high-intensity statins. Non-statin therapies could be viable options in this population if more was understood about their ability to lower ASCVD risk and safety profiles. Nevertheless, lipid-lowering agents remain an integral component of the overall strategy to reduce atherogenic burden in older adults. Future research in this area should aim to enroll more older adults in clinical trials, determine the utility of ASCVD risk estimation for primary prevention, and investigate the role of non-statin therapies in this population.

show abstract

Section: Statin-associated Muscle Effectsmentioning

confidence: 95%

Current Drug Treatment of Hyperlipidemia in Older Adults

2015

View full text Add to dashboard Cite

show abstract

“…For normal healthy individuals who are eager to achieve primary prevention, we discovered that for every 10,000 people taking a statin, there were 307 extra patients with cataracts, 23 additional patients with acute kidney failure and 74 extra patients with liver dysfunction [6][7][8]. Furthermore, statin therapy increased muscle fatigabilty by 30% [9,10] with 11.3% incidence of rhabdomyolysis at high doses.…”

Section: Review Of the Statin Sagamentioning

confidence: 99%

The Ugly Side of Statins. Systemic Appraisal of the Contemporary Un-Known Unknowns

Sultan¹,

Hynes²

2013

OJEMD

View full text Add to dashboard Cite

Cardio-vascular specialists have witnessed and actively participated in the revolutionary developments that have occurred in their field of specialization over the last few years. Cutting-edge technologies have led to dramatic improvements in life-expectancy and quality of life. An open-mind and pioneering attitude are necessary when exploring new frontiers to improve our patients' health. However, naïve indiscriminate acceptance of novel mainstream therapies is not always advisable and prudence is required in unearthing harmful, covert side effects. An objective review of contemporary vascular research was performed and industrial bias was sifted out for a fresh prospective on how to promote primary cardiovascular prevention with attainable lifestyle adjustments [1]. A comprehensive review of Pubmed, EM-BASE and Cochrane review databases was undertaken for articles relating to cardiovascular primary prevention and statin side effects with the aim of harmonising their roles within contemporary clinic practice. Particular attention was paid to large-scale randomised controlled trials on contemporary cardiovascular pharmacotherapies and their specific adverse effects on metabolic pathways which feature prominently in cardiovascular primary prevention and regenerative programmes. There is a categorical lack of clinical evidence to support the use of statin therapy in primary prevention. Not only is there a dearth of evidence for primary cardiovascular protection, there is ample evidence to show that statins actually augment cardiovascular risk in women, patients with Diabetes Mellitus and in the young. Furthermore statins are associated with triple the risk of coronary artery and aortic artery calcification. Cardiovascular primary prevention and regeneration programmes, through life style changes and abstaining from tobacco use have enhanced clinical efficacy and quality of life over any pharmaceutical or other conventional intervention.

show abstract

“…Moreover, as predicted, new updated guidelines will most likely increase statin prescription by physicians [3]. However, besides the beneficial outcomes, statins also produce a number of adverse effects [4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20] that may compromise medication compliance and quality of life in certain statin users. Moreover, the issue is further complicated by the clinical availability of statins with various biochemical characteristics (Table 1), which determines the effectiveness and tissue distribution of the drug and affects myotoxic potential [21,22].…”

Section: Introductionmentioning

confidence: 99%

The Effects of Statin Medications on Aerobic Exercise Capacity and Training Adaptations

Murlasits

Radák

2014

Sports Med

View full text Add to dashboard Cite

The incidence of myopathy increases dramatically in statin users who also exercise, likely limiting the positive impact of this lifesaving medication. New evidence also indicates that statin use can directly compromise aerobic exercise capacity; however, we are just beginning to understand the interactions of statins with exercise training and adaptations. This review focuses on the interactions of statins with aerobic exercise capacity and training adaptations to summarize the available information and draw attention to the gaps in our current knowledge in this area. PubMed, Web of knowledge, and Google scholar databases were searched between January 2000 and December 2013 using the following terms and their combinations: statins, exercise, aerobic capacity, endurance training, adaptations. The reference lists of the relevant articles were also scanned for additional information. Considering the widespread use of statins and the need for exercise for cardiovascular health, a better understanding of the interactions of these interventions as well as practical solutions are needed to reduce statin adverse effects associated with exercise.

show abstract

Prevalence and risk factors of muscle complications secondary to statins

Abstract: Adverse reactions to statins may be more common than previously reported, and they may be affected by specific patient and disease characteristics.

Cited by 74 publications

References 36 publications

Current Drug Treatment of Hyperlipidemia in Older Adults

Current Drug Treatment of Hyperlipidemia in Older Adults

The Ugly Side of Statins. Systemic Appraisal of the Contemporary Un-Known Unknowns

The Effects of Statin Medications on Aerobic Exercise Capacity and Training Adaptations

Contact Info

Product

Resources

About